These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39263027)

  • 21. Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer.
    Li S; Dong D; Geng J; Zhu X; Shi C; Zhang Y; Wang H; Zhou S; Wu H; Cai Y; Li Y; Wang W
    Front Oncol; 2019; 9():1080. PubMed ID: 31681609
    [No Abstract]   [Full Text] [Related]  

  • 22. Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer.
    Punjabi A; Barrett E; Cheng A; Mulla A; Walls G; Johnston D; McAleese J; Moore K; Hicks J; Blyth K; Denholm M; Magee L; Gilligan D; Silverman S; Qureshi M; Clinch H; Hatton M; Philipps L; Brown S; O'Brien M; McDonald F; Faivre-Finn C; Hiley C; Evison M
    Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):e331-e338. PubMed ID: 33863615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases.
    Kim D; Fuster MM; Nath SK; Bharne A; Read W; Bazhenova L; Song WY; Mundt AJ; Sandhu AP
    J Radiosurg SBRT; 2012; 2(1):63-72. PubMed ID: 29296343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of absolute lymphocyte count in patients with advanced esophageal cancer treated with immunotherapy: a retrospective analysis.
    Zhao Q; Bi Y; Xue J; Liu Y; Zhu J; Qin S
    Ann Transl Med; 2022 Jul; 10(13):744. PubMed ID: 35957729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors.
    Ji X; Zhao Y; Zhu X; Shen Z; Li A; Chen C; Chu X
    Front Oncol; 2020; 10():595781. PubMed ID: 33585211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic Body Radiation Therapy for Pulmonary Oligometastases Arising from Non-lung Primaries in Patients Without Extrapulmonary Disease.
    Dohopolski MJ; Horne Z; Clump D; Burton SA; Heron DE
    Cureus; 2018 Feb; 10(2):e2167. PubMed ID: 29644155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
    Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
    BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio predicts post-stereotactic radiosurgery survival of patients with brain metastases concurrently treated with immune checkpoint inhibitors.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2024 Aug; ():1-10. PubMed ID: 39178473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy.
    Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
    Acta Oncol; 2018 Aug; 57(8):1031-1037. PubMed ID: 29488414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer stereotactic body radiation therapy: a retrospective study.
    Chen M; Chen K; Li S; Meng Y; Shi Y; Chen X; Yang H
    J Thorac Dis; 2022 Feb; 14(2):494-506. PubMed ID: 35280472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
    Tokunaga E; Miyoshi Y; Dozono K; Kawaguchi T; Toi M
    Oncologist; 2024 Mar; 29(3):e319-e329. PubMed ID: 37971418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.
    Liu J; Gao D; Li J; Hu G; Liu J; Liu D
    Onco Targets Ther; 2022; 15():1161-1170. PubMed ID: 36238132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT.
    Alagappan M; Pollom EL; von Eyben R; Kozak MM; Aggarwal S; Poultsides GA; Koong AC; Chang DT
    Am J Clin Oncol; 2018 Mar; 41(3):242-247. PubMed ID: 26757436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy.
    Giuliani M; Sampson LR; Wong O; Gay J; Le LW; Cho BC; Brade A; Sun A; Bezjak A; Hope AJ
    Curr Oncol; 2016 Aug; 23(4):e362-8. PubMed ID: 27536185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 39. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China.
    Xu C; Zhao X; Ju X; Shen Y; Qu M; Ye Y; Wang X; Yu C; Gao X; Zhang H
    Front Oncol; 2022; 12():879310. PubMed ID: 35574331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.